This patient-specific “molecular risk” in ALK+ NSCLC appears to impair efficacy of all treatments analyzed so far, and cannot therefore be used for selection of specific pharmaceuticals yet [19]. This evidence concerns the gene ALK and non-small cell lung carcinoma.